

Title: Chimeric Antigen Receptor (CAR) T-cell Therapy for Cancers (CAG-00451N)

Decision: The Centers for Medicare & Medicaid Services (CMS) covers Chimeric Antigen Receptor (CAR) T-cell Therapy for Cancers with T-cells expressing at least one chimeric antigen receptor (CAR) when administered at healthcare facilities enrolled in the FDA risk evaluation and mitigation strategies (REMS) and is used for either an FDA-approved indication (according to the FDA-approved label for that product), or for other uses when the product has been FDA-approved and the use is supported in one or more CMS-approved compendia. The use of non-FDA-approved autologous T-cells expressing at least one CAR is non-covered.

What this means: Chimeric Antigen Receptor (CAR) T-cell Therapy for cancer may be covered for a member if the healthcare facility is certified to dispense and administer the drug and the drug is FDA approved for the member's diagnosis and condition. Please refer to the final decision memo for all coverage criteria.

Effective: August 7, 2019

This announcement can be found at: [Decision Memo for Chimeric Antigen Receptor \(CAR\) T-cell Therapy for Cancers \(CAG-00451N\)](#)

HealthPartners is a health plan that contracts with both Medicare and the Minnesota Medical Assistance (Medicaid) program to provide benefits of both programs to enrollees. HealthPartners is also a Cost plan and PPO plan with a Medicare contract. Enrollment in HealthPartners depends on contract renewal. HealthPartners UnityPoint Health is a PPO plan with a Medicare contract. Enrollment in HealthPartners UnityPoint Health depends on contract renewal.

H2462_90242 IR Approved 06/2015
H3416_90242 IR Approved 06/2017
H2422_90242 IR Approved 07/2015
H4882_90242 IR Approved 03/2018